METHOD FOR PREDICTION OF RESPONSE TO FIRST-LINE POLYCHEMOTHERAPY ACCORDING TO THE BEACOPP-14 SCHEME OF PATIENTS WITH NODULAR SCLEROSIS OF CLASSICAL HODGKIN'S LYMPHOMA BY MORPHOMETRIC ASSESSMENT OF RELATIVE CONTENT OF CD20, CD4 AND CD8-POSITIVE CELLS OF THE MICROENVELOPMENT Russian patent published in 2025 - IPC G01N33/483 G01N33/68 G01N1/30 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology, and can be used for prediction of response to first-line polychemotherapy according to the scheme BEACOPP-14 of patients with nodular sclerosis of classical Hodgkin's lymphoma. In the histological sections of the lymph nodes, the average relative content of CD20, CD4 and CD8-positive cells is calculated after immunohistochemical staining of the lymph nodes, followed by the calculation of a percentage index (PI) of the above microenvelopment cells. If the PI is more than or equal to 0.9, a complete response to the first-line polychemotherapy according to the BEACOPP-14 scheme is predicted. If the PI value is less than 0.9, the insufficient or partial response to the first-line polychemotherapy according to the BEACOPP-14 regimen or the absence thereof is predicted.

EFFECT: method enables predicting the response to the first-line therapy of the patients with nodular sclerosis of classical Hodgkin's lymphoma by morphometric assessment of the relative content of CD20, CD4 and CD8-positive cells of the microenvelopment with calculation of their PI.

1 cl, 2 ex